Visual Outcomes of Vivity in Patients With Well Controlled Glaucoma

• Conditions: Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

• Registration Number: NCT05075226
• Lead Sponsor: Maisonneuve-Rosemont Hospital

Brief Summary

Glaucoma is a progressive optic neuropathy that results in a loss of contrast sensitivity and visual field if not detected and treated. When glaucoma patients undergo cataract surgery, they are often not ideal candidates for many existing presbyopia correcting IOLs as they reduce contrast sensitivity because of the splitting of light and are more likely to have visual disturbances secondary to diffractive steps in the IOL design. This is largely because of a higher rate of ocular surface disease and meibomian gland dysfunction in this patient population due to the chronic utilization of topical drops. As a result of this, patients with glaucoma currently receive aspheric monofocal IOLs during cataract surgery, which are lenses with minimal loss of contrast sensitivity but only one point of focus (typically targeted for distance). This necessitates the use of glasses for near and intermediate vision and has an impact on quality of life for these patients.

The Vivity Extended Depth of Focus (EDOF) IOL is a new technology that maintains uncompromised distance vision and provides improved intermediate vision correction, reducing the need for glasses. This lens uses a new optical system with no diffractive steps in the IOL; trials in non-glaucomatous patients have shown the rate of visual aberrations to be comparable to an aspheric monofocal IOL which are currently the standard of care in patients with glaucoma. There is no published data on outcomes of this IOL in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT). Studies are required to evaluate the clinical success of this new lens technology in glaucomatous patients. This will be the first study in Canada to report clinical outcomes of the Vivity IOL in this patient cohort.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-29
• Status Verified: 2021-09
• Study First Submitted: 2021-09-29
• Study First Submitted QC: 2021-09-29
• Last Update Submitted: 2021-09-29
• Study First Posted: 2021-10-12
• Last Update Posted: 2021-10-12
• Primary Completion: 2022-07-30
• Study Completion: 2022-08-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Age greater than 18 years
• Patients undergoing uncomplicated cataract surgery with IOL implantation
• Patients with both eyes that calculate for IOL powers in the following ranges: 15-25D spherical power (for Vivity)
• Patients possessing with-the-rule or against-the-rule astigmatism ≤2.50 D
• Well controlled OAG or OHT defined as IOP less than or equal to 18mmHg
• Mild to moderate glaucoma as defined by MD VF loss less than 12 dB and no VF defect within the central 5 degrees with 0dB or less than 15dB of both hemi-fields in the central 5 degrees

Exclusion Criteria

• Ocular comorbidity that might hamper post-operative visual acuity (ie. Macular degeneration, macular edema, uveitis, corneal dystrophy, diabetic retinopathy)
• Ocular trauma or zonula instability
• Previous refractive surgery
• Irregular corneal astigmatism and keratoconus
• Difficulties comprehending written or spoken English or French language
• Patients with physical or intellectual disability
• Patients unable to fixate
• Patients with uncontrolled glaucoma or advanced glaucoma
• Patients that are undergoing filtration or tube surgery or MIGS devices for glaucoma
• Patients with previous filtration or tube surgery for glaucoma
• Patients with unreliable biometry
• Severe dry eye disease or ocular surface disease
• Patients where Barrett Toric Calculator recommends T5 or higher toric IOL

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Binocular uncorrected visual acuity	3 months	Binocular uncorrected visual acuities at near distance (40cm) will be measured

Secondary Outcome Measures

Name	Time	Method
IOP (mmHg at 1 day, 1 month and 3 months)	3 months	IOP will be measured in mmHg
Severity, frequency of bothersomeness of starbursts, haloes, and glare	3 months	Severity, frequency of bothersomeness of starbursts, haloes, and glare will be evaluated using the QUVID questionnaire
Spectacle independence	3 months	Spectacle independence will be evaluated using the IOLSAT questionnaire
IOP	1 month	IOP will be measured in mmHg
Mean refractive outcomes	3 months	Mean refractive outcomes (error and MRSE) will be evaluated
Refractive target accuracy	Approximate patient follow-up time is 4 months following phacoemulsification and insertion of the study lens in the second eye. Time in between eyes will be approximately 1-2 months.	Percentage of eyes with an APE of 0.50D or less
Contrast sensitivity	3 months	Contrast sensitivity will be evaluated using the Pelli-Robson Chart

Trial Locations

Locations (1)

Clinique Bellevue; 🇨🇦 Montréal, Quebec, Canada